(PANTOPRAZOLE 40 MG & DOMPERIDONE 10 MG)
M.R.P: – 650
Pantoprazole is a proton pump inhibitor drug used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease whereas Domperidone is a specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms. Pantoprazole acts by selectively inhibiting the H+/K+-ATPase enzyme in the secretory canaliculus of the stimulated parietal cell. Domperidone stimulates GI activity by acting as a competitive antagonist at dopamine D2-receptors.
Pantoprazole: – is a proton pump inhibitor (PPI) that suppresses the final step in gastric acid production. Pantoprazole is unstable in acid and is administered orally in the form of an enteric-coated tablet Pantoprazole is completely and rapidly absorbed after oral administration. The absolute bioavailability from the tablet was found to be about 77 %. Pantoprazole is extensively metabolized in the liver through the cytochrome P450 (CYP) system. Renal elimination represents the major route of excretion (about 80%) for the metabolites of Pantoprazole; the rest is excreted with the faeces.
Domperidone: Domperidone acts as a gastrointestinal emptying (delayed) adjunct and peristaltic stimulant. The gastroprokinetic properties of Domperidone are related to its peripheral dopamine receptor blocking properties.. In fasting subjects, Domperidone is rapidly absorbed after oral administration. Domperidone is 91-93% bound to plasma proteins. Domperidone undergoes rapid and extensive hepatic metabolism and Urinary and faecal excretions amount to 31 and 66% of the oral dose respectively.
2. Antireflux Agents & Antiulcerants / GIT Regulators,